Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
ATNM
ATNM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
ATNM News
ATNM-400 Demonstrates Potent Efficacy in Prostate Cancer
Jun 03 2026
Newsfilter
Actinium Secures Two Patent Allowances in Canada
May 29 2026
Newsfilter
SLS and ATNM Present Key Data Catalysts Ahead of AACR Summit
Apr 20 2026
stocktwits
Actinium Pharmaceuticals Unveils Promising Data for ATNM-400 and Actimab-A
Apr 06 2026
Newsfilter
Healthcare Stocks with Strong Earnings Momentum Earn A+ EPS Revision Grades
Jan 16 2026
seekingalpha
FibroBiologics (FBLG) Stock Rises 7.68%, Attracts Market Attention
Jan 13 2026
NASDAQ.COM
Actinium Presents ATNM-400 Breast Cancer Data, Demonstrating Strong Anti-Tumor Activity
Dec 12 2025
PRnewswire
Actinium Presents New ATNM-400 Breast Cancer Data Showing Potent Efficacy
Dec 12 2025
Newsfilter
Actinium Pharmaceuticals, Inc. to Showcase ATNM-400 Findings for Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Broadening Pan-Tumor Profile Across Three Solid Tumor Types
Nov 04 2025
Newsfilter
Actinium Pharmaceuticals Unveils New Findings Showcasing Strong and Lasting Effectiveness of ATNM-400, a Pioneering Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Oct 24 2025
Newsfilter
Actinium Pharmaceuticals to Present Data on ATNM-400, a Novel Actinium-225 Radiotherapy for Multiple Tumors, in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Treatments
Oct 13 2025
Newsfilter
Actinium to Showcase ATNM-400 Preclinical Findings Demonstrating Long-lasting Tumor Control and Efficacy Against Resistance to Standard Prostate Cancer Treatments at the 32nd Annual Prostate Cancer Foundation Scientific Retreat
Oct 13 2025
Newsfilter
Actinium: Q2 Earnings Snapshot
Aug 08 2025
Yahoo Finance
HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $4 Price Target
Jun 24 2025
Benzinga
Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting
Jun 23 2025
Newsfilter
Life Sciences Investor Forum: Now Available for Online Viewing
Jun 13 2025
Newsfilter
Show More News
